Evaluating Cancer Survivorship Care Models

NCT ID: NCT02362750

Last Updated: 2016-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

992 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Evaluating Cancer Survivorship Care Models project is an innovative 3-year study that is collecting data to help understand how to best deliver follow-up care to cancer survivors. Cancer is a complex disease requiring complex treatments that can cause lasting impacts after treatment ends. Some patients face physical, psychosocial, spiritual and/or practical challenges as they adjust to life after cancer. Fortunately, health care providers have begun to focus on the consequences of cancer and its treatment and are more actively working with cancer survivors to manage post-treatment needs and care.

Led by the George Washington University and funded by the Patient-Centered Outcomes Research Institute, this project brings together representatives from the Commission on Cancer, the Cancer Support Community, LIVESTRONG and the American Cancer Society as well as cancer survivors and healthcare professionals to better understand how different strategies or models of care impact outcomes that are most important to cancer survivors. The project will focus on survivors of breast, prostate and colorectal cancers and will be relevant for understanding the needs and preferences of survivors of other cancers as well. The emphasis is on patient-centered outcomes, which are outcomes that are most significant to patients, such as patient satisfaction and quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evaluating Cancer Survivorship Care Models Study Overview and Research Design

Cancer is a complex disease requiring complex treatments that can cause lasting impacts after treatment ends. Some patients face lasting physical, psychosocial, spiritual and/or practical challenges as they adjust to life after cancer. Fortunately, health care clinicians have begun to focus on the consequences of cancer and its treatment and are more actively working with cancer survivors to manage post-treatment needs and care.

The Evaluating Cancer Survivorship Care Models project is a groundbreaking 3-year comparative effectiveness research (CER) study that examines how to best deliver follow-up care to cancer survivors. This project is led by the George Washington University and funded by the Patient-Centered Outcomes Research Institute. A key component of the project is the use of a stakeholder Advisory Board chaired by a cancer survivor who serves as a senior advisor to the research team. The Advisory Board includes survivors, survivor advocates, clinicians, health care professionals and advisors from stakeholders across myriad facets of cancer care, including the Cancer Support Community, LIVESTRONG, the Commission on Cancer, and the American Cancer Society. These organizations are critical to the success of the project.

The study is innovative in its focus on patient-centered outcomes. The first phase of the project employed a mixed methods approach including a secondary analysis of existing data from 4 national surveys, focus groups with cancer survivors, an environmental scan of existing survivorship programs and a national survey of cancer survivors to develop an outcomes tool and a prospective observational CER study. Based on results from the first phase, the study team at the George Washington University (GW) developed a patient-prioritized index to identify services and components of care that patients equate with high quality survivorship care.

Three models of survivorship care at Commission on Cancer-accredited institutions were identified through the environmental scan. In the CER phase of the study, each survivorship care model will serve as a comparator for the other two models. Patients in the CER study population will be adults who have been diagnosed with non-metastatic breast, prostate or colorectal cancer and completed active treatment. Patient-reported outcomes will be assessed at three points in the project: at baseline (immediately prior to and immediately following a post-treatment survivorship visit), 3 months post-visit and 6 months post-visit. Multivariable analyses including repeated measures and mixed-effect regression modeling will be used to control for systematic differences across the groups, which would further increase the validity of our results. Using the newly-developed index, the comparative effectiveness study will measure the quality of programs according to what patients have identified as most important to them.

The investigators have launched the CER phase of the study and are enrolling high-performing survivorship programs. Our pool of invited participants consists of Commission on Cancer-accredited sites with clinical survivorship care programs that meet the following eligibility criteria:

* Provide services to survivors of breast, prostate or colorectal cancer
* Have demonstrated a high performance level on incorporating elements of survivorship care into clinical care delivery
* See at least 60 new survivors yearly
* Includes the most common characteristics related to delivery of survivorship care

During the CER study, data will be gathered from survivorship program administrators, patients and survivorship care clinicians. Survivorship program administrators will complete an interview and survey to examine how survivorship programs are organized and identify key characteristics of programs to determine which factors are most influential in delivering high quality post-treatment survivorship care. Patients will complete surveys measuring patient-centered outcomes: health-related quality of life; self-efficacy; satisfaction; health care utilization and a newly developed measure of quality of survivorship care as prioritized by patients. Clinicians will complete surveys on the services offered during participating patients' initial post-treatment survivorship visit. Together, this data will allow the GW study team to understand successful strategies for transforming the care delivery system to be more responsive to patient needs.

In the third and final phase, this project will generate critical data for a variety of decision-makers related to care for post-treatment cancer survivors and will result in evidence-based guidance for how to organize and deliver post-treatment care. The GW study team seeks to provide recommendations on survivorship care delivery best practices; develop tools for improving survivorship programs and care delivery from both clinician and patient perspectives; and to widely disseminate findings to a variety of stakeholders, including survivors and their families, clinicians, survivorship care program leaders, payers, policymakers and others.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Quality of Life Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

comparative effectiveness survivorship Patient-Centered Outcomes Research

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participating Program Administrators

Eligible survivorship program administrators at selected Commission on Cancer-accredited institutions will complete an organizational interview and organizational survey.

Organizational Interview

Intervention Type OTHER

Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.

Organizational Survey

Intervention Type OTHER

Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.

Participating Cancer Survivors

Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions will complete four surveys:

Survivor Survey (1): Pre-Visit Baseline Survivor Survey (2): 1 Week Post-Visit Survivor Survey (3): 3 Months Post-Visit Survivor Survey (4): 6 Months Post-Visit

Survivor Survey (1): Pre-Visit Baseline

Intervention Type OTHER

Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Survivor Survey (2): Post-Visit

Intervention Type OTHER

Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Survivor Survey (3): 3 Month Post-Visit

Intervention Type OTHER

Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Survivor Survey (4): 6 Month Post-Visit

Intervention Type OTHER

Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Participating Clinicians

Survivorship clinicians from clinical survivorship programs at selected Commission on Cancer-accredited institutions will complete a clinician survey.

Clinician Survey

Intervention Type OTHER

Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Organizational Interview

Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.

Intervention Type OTHER

Organizational Survey

Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.

Intervention Type OTHER

Survivor Survey (1): Pre-Visit Baseline

Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Intervention Type OTHER

Survivor Survey (2): Post-Visit

Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Intervention Type OTHER

Survivor Survey (3): 3 Month Post-Visit

Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Intervention Type OTHER

Survivor Survey (4): 6 Month Post-Visit

Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.

Intervention Type OTHER

Clinician Survey

Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Survivorship program administrators oversee survivorship programs which:

* See at least 60 new survivors of non-metastatic breast, prostate or colorectal cancer or survivors of any type of cancer yearly
* Represent one of the clinical survivorship care models identified in our environmental scan
* Indicate a high performance level on incorporating elements of survivorship care into clinical care delivery.

Survivors:

* English-speaking survivors of non-metastatic breast, prostate or colorectal cancers
* Completed planned active treatment (chemotherapy, radiation, and/or surgery) with the exception of hormonal medication, aromatase inhibitors or other maintenance therapy
* Diagnosed at 18 years old or older
* First appointment with the survivorship program is planned but has not yet been completed

Survivorship program clinicians:

• Must be providing services for eligible survivors who have completed their first visit with the survivorship program and are participating in the study.

Exclusion Criteria

Survivorship program administrators:

* Programs with fewer than at least 60 new survivors yearly
* Do not provide services to adult survivors of non-metastatic breast, prostate or colorectal cancer or survivors of any type of cancer
* Do not represent one of the three models of clinical survivorship care as identified in our environmental scan
* Do not indicate a high performance level on incorporating elements of survivorship care into clinical care delivery

Survivors:

* Received diagnosis for cancer that was not breast, prostate or colorectal cancer
* Not English-speaking
* Currently undergoing active treatment (defined as chemotherapy, radiation, and/or surgery)
* Cancer has metastasized
* Diagnosed at under 18 years old
* Have completed first appointment with the survivorship program

Men will be excluded from the breast cancer arm of the study. Women will be excluded from the prostate cancer arm of the study.

Survivorship program clinicians:

• Not providing services for eligible survivors.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

George Washington University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

K. Holly Mead, PhD

Role: PRINCIPAL_INVESTIGATOR

The George Washington University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The George Washington University

Washington D.C., District of Columbia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Mead KH, Wang Y, Cleary S, Arem H, Pratt-Chapman ML. Defining a patient-centered approach to cancer survivorship care: development of the patient centered survivorship care index (PC-SCI). BMC Health Serv Res. 2021 Dec 18;21(1):1353. doi: 10.1186/s12913-021-07356-6.

Reference Type DERIVED
PMID: 34922530 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ncbi.nlm.nih.gov/books/NBK196214/

Viswanathan M, Halpern M, Swinson Evans T, et al. Models of Cancer Survivorship Care \[Internet\]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Mar. (Technical Briefs, No. 14.)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IH-12-11-5255

Identifier Type: -

Identifier Source: org_study_id